2 Minute Medicine Rewind April 29, 2019
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease Alzheimer disease (AD) is characterized by the ...
Tag: rivaroxaban
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
1. In this post-hoc analysis of data from the NAVIGATE-ESUS trial, which evaluated strategies to prevent recurrent stroke in patient ...
![siRNA against antithrombin alleviates symptoms of hemophilia [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2015/04/clot-CCWiki-350x250.jpg)
Rivaroxaban does not decrease rates of venous thromboembolism complications after hospital discharge
1. At a median follow-up of 3.3 years, rates of symptomatic venous thromboembolism or death due to thromboembolism were similar ...
Lack of superiority of rivaroxaban for secondary prevention of embolic stroke of undetermined source
1. At a median follow-up of eleven months, rivaroxaban was not superior to aspirin for prevention of secondary stroke after ...
Aspirin comparable to rivaroxaban for extended venous thromboembolism prophylaxis following arthroplasty: The EPCAT II trial
1. Patients initially treated with rivaroxaban following total knee or hip arthroplasty experienced similar rates of venous thromboembolism (VTE) regardless ...
Extended rivaroxaban superior to aspirin in lowering risk of recurrent venous thromboembolism: The EINSTEIN CHOICE trial
1. The EINSTEIN CHOICE trial involved patients who had a history of venous thromboembolism (VTE) and had completed 6 to ...
Triple therapy with rivaroxaban reduces bleeding compared to warfarin: The PIONEER AF-PCI trial
1. In patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI), treatment with rivaroxaban, in addition to dual ...
Rivaroxaban associated with increased bleeding risk compared with dabigatran in nonvalvular atrial fibrillation
1. Based on a retrospective cohort study of US Medicare patients, rivaroxaban was associated with a significantly increased risk of ...
The EINSTEIN-PE trial: Rivaroxaban to treat pulmonary embolism [Classics Series]
Image: PD 1. Rivaroxaban, an oral factor Xa inhibitor, was non-inferior to standard anticoagulation therapy (i.e. low-molecular weight heparin and ...
The EINSTEIN-DVT trial: Rivaroxaban in acute deep-vein thrombosis [Classics Series]
Image: PD 1. Rivaroxaban is non-inferior to standard therapy of enoxaparin and vitamin K antagonist in treating acute, symptomatic deep-vein ...
